Praxis Precision Medicines, Inc. Q2 FY2025 earnings call

• Praxis has 4 late-stage assets for CNS disorders and expects 5 clinical readouts in the next year, with cash runway extending into 2028.
• Vormatrigine showed best-in-disease efficacy in the RADIANT study: median seizure reduction over 56%, 60% of patients achieved at least 50% seizure reduction, over 22% seizure-free in the second month of treatment. Enrolled a representative refractory epilepsy population with high baseline seizure burden.
• Safety of vormatrigine was favorable with mild to moderate adverse events, though 23% discontinuation rate linked to background ASM dose adjustment issues. Proactive reduction of background ASMs avoided adverse events/discontinuations in 6 instances.
• Plan to add 40 mg dose arm to POWER2 study, include depression and mood endpoints in POWER2, and launch POWER3 study for vormatrigine as stand-alone therapy. Relutrigine granted breakthrough designation for SCN2A and SCN8A patients.

No detailed financial performance for product segments provided in the transcript. Focus is mainly on the vormatrigine study within the company's CNS disorder drug development.

• POWER1 expected to finalize enrollment and have data by end of 2025.
• POWER2 finishing in back half of 2026, enrolling approximately 400 refractory epilepsy patients with 20, 30, or 40 mg doses of vormatrigine against placebo over 12 weeks.
• POWER3 to initiate in early 2026.

• Discontinuation rate in RADIANT study linked to lack of background ASM dose adjustment despite protocol guidance. However, this was seen as manageable with appropriate background therapy management.
• Potential challenges in recruiting patients for some studies compared to competitors, but Praxis attributes strong enrollment to factors like positive patient and investigator feedback on mood improvements.

Q: Yasmeen Rahimi asked about differences in response rates based on background therapies and the execution of RADIANT.

A: Marcio De'Souza responded on robust responses across different background therapies and highlighted strong enrollment execution for RADIANT and plans for POWER1.

Q: Ritu Baral asked about the increase in efficacy and exposure response analysis.

A: Marcio De'Souza and Steve Petrou discussed steady-state reaching quickly, exposure response analysis underway, and reasons for the phenomenal results.

Q: Joon Lee asked about discontinuation rates in RADIANT and POWER1 placebo rates.

A: Marcio De'Souza talked about discontinuation rates linked to background ASM issues and expectations for lower placebo rates in POWER1 due to patient population and site quality.

Q: Douglas Tsao asked about side effect profile and mood benefits.

A: Steven Petrou discussed vormatrigine's unique sodium channel interaction and positive mood feedback from investigators. Marcio De'Souza mentioned lack of initial mood assessment instruments but noted systematic reporting in future studies.

Q: Yatin Suneja asked about response kinetics and generalized data.

A: Marcio De'Souza and Steven Petrou discussed deepening efficacy over time and expectations for generalized data read-through.

Q: David Hoang asked about mood endpoints and monotherapy.

A: Marcio De'Souza talked about adding mood endpoints to labels and the market opportunity for vormatrigine as monotherapy.

Q: Ami Fadia asked about background therapy discontinuation and POWER3.

A: Marcio De'Souza discussed reasons for background therapy adjustments and enthusiasm for POWER3 due to vormatrigine's potential.

Q: Jay Olson asked about disease-modifying benefit.

A: Marcio De'Souza and Steven Petrou discussed seizure reduction leading to disease modification by reversing the hyperexcitable brain state.

Q: Brian Skorney asked about focal onset patients and safety.

A: Marcio De'Souza confirmed all patients in RADIANT were focal onset and discussed safety despite aggressive background therapies.

Q: Rudy Li asked about background therapy impact and enrollment criteria.

A: Marcio De'Souza stated no concerns about combination therapy and current enrollment aligns with market treatment practices.

Q: Ritu Baral asked about side effect details.

A: Marcio De'Souza discussed mild to moderate adverse events, their resolution, and that most were not related to vormatrigine itself.